Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D011464:Epoprostenol / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007511:Ischemia / Q000188:drug therapy; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000008:administration & dosage*; D011897:Random Allocation; D011928:Raynaud Disease / Q000188:drug therapy*; D012867:Skin / Q000098:blood supply; D012881:Skin Temperature
D011453:Prostaglandins; D011464:Epoprostenol